Comment
doi: 10.1038/s41577-020-0334-1.
Inactivated vaccine for SARS-CoV-2
Affiliations
- PMID: 32355330
- PMCID: PMC7192055
- DOI: 10.1038/s41577-020-0334-1
Item in Clipboard
Comment
Inactivated vaccine for SARS-CoV-2
Nat Rev Immunol.
2020 Jun.
No abstract available
Conflict of interest statement
The author declares no competing interests.
Comment on
-
Development of an inactivated vaccine candidate for SARS-CoV-2.Science. 2020 Jul 3;369(6499):77-81. doi: 10.1126/science.abc1932. Epub 2020 May 6. Science. 2020. PMID: 32376603 Free PMC article.
Similar articles
-
A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine.bioRxiv [Preprint]. 2020 Jul 31:2020.07.30.229120. doi: 10.1101/2020.07.30.229120. bioRxiv. 2020. Update in: Vaccines (Basel). 2020 Dec 17;8(4):E771. doi: 10.3390/vaccines8040771. PMID: 32766572 Free PMC article. Updated. Preprint.
-
A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine.Vaccines (Basel). 2020 Dec 17;8(4):771. doi: 10.3390/vaccines8040771. Vaccines (Basel). 2020. PMID: 33348607 Free PMC article.
-
The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET.Structure. 2020 Nov 3;28(11):1218-1224.e4. doi: 10.1016/j.str.2020.10.001. Epub 2020 Oct 15. Structure. 2020. PMID: 33058760 Free PMC article.
-
Frontrunners in the race to develop a SARS-CoV-2 vaccine.Can J Microbiol. 2021 Mar;67(3):189-212. doi: 10.1139/cjm-2020-0465. Epub 2020 Dec 2. Can J Microbiol. 2021. PMID: 33264067 Review.
-
[The Challenges of Vaccine Development Against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector].Mol Biol (Mosk). 2020 Nov-Dec;54(6):922-938. doi: 10.31857/S0026898420060154. Mol Biol (Mosk). 2020. PMID: 33276356 Review. Russian.
Cited by
-
Adaptive immune responses and cytokine immune profiles in humans following prime and boost vaccination with the SARS-CoV-2 CoronaVac vaccine.Virol J. 2022 Dec 22;19(1):223. doi: 10.1186/s12985-022-01957-1. Virol J. 2022. PMID: 36550578 Free PMC article.
-
Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects.Front Bioeng Biotechnol. 2022 Aug 9;10:921755. doi: 10.3389/fbioe.2022.921755. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 36017347 Free PMC article. Review.
-
Promising use of immune cell-derived exosomes in the treatment of SARS-CoV-2 infections.Clin Transl Med. 2022 Aug;12(8):e1026. doi: 10.1002/ctm2.1026. Clin Transl Med. 2022. PMID: 35988156 Free PMC article. Review.
-
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.Vaccine. 2022 Aug 19;40(35):5263-5274. doi: 10.1016/j.vaccine.2022.06.006. Epub 2022 Jun 15. Vaccine. 2022. PMID: 35715351 Free PMC article. Clinical Trial.
-
Yeasts in nanotechnology-enabled oral vaccine and gene delivery.Bioengineered. 2021 Dec;12(1):8325-8335. doi: 10.1080/21655979.2021.1985816. Bioengineered. 2021. PMID: 34592900 Free PMC article. Review.
References
-
- Gao Q, et al. Rapid development of an inactivated vaccine for SARS-CoV-2. bioRxiv. 2020 doi: 10.1101/2020.04.17.046375. - DOI
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
